A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

NCT04688021 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Graft-versus-host-disease

Interventions

DRUG: Cytarabine
DRUG: Busulfan
DRUG: Cyclophosphamide
DRUG: Me-CCNU
DRUG: Rabbit antithymocyte globulin
DRUG: Tocilizumab
PROCEDURE: Allogeneic HSCT
DRUG: Cyclosporin A
DRUG: Mycophenolate Mofetil
DRUG: MTX

Sponsor

Yi Luo